Femasys Inc. news

ATLANTA, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women`s needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced the appointment of Dov Elefant to chief financial officer (CFO), to be effective February 28, 2022. Mr. Elefant has 25 years of financial management experience at both public and private biopharmaceutical companies.

Industry leader Wendy Perrow brings decades of expertise in fundraising, global product launches and corporate strategy to the Femasys team

ATLANTA, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women`s needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced the appointment of a new board member, Wen

FemTech Focus is a 501c3 non-profit organization founded to empower, equip, and bring together healthcare professionals, life-science entrepreneurs, and forward thinking investors to revolutionize women’s health and wellness. FemTech Focus elevates the FemTech industry through increased awareness, providing resources to FemTech founders, & creating opportunities to support FemTech startups through exposure, networking, and access to capital.The FemTech Focus Podcast with Dr. Brittan

First in Class Insemination Treatment for Infertility

LOCAL Pivotal Trial to Enroll Up to 792 Patients Across 20 U.S. Centers

Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on transforming women`s healthcare, today announced the initiation and first patient treated in a pivotal trial evaluating FemaSeed, a first in class, localized directional insemination product candidate for infertility.

“For more than 20 years, current approaches to infert